LRRC32 antibody

Catalog No. ABIN2664991

The Rat Monoclonal anti-LRRC32 antibody has been validated for IHC, CyTOF and ELISA (Capture). It is suitable to detect LRRC32 in samples from Mouse.

Quick Overview for LRRC32 antibody (ABIN2664991)

Target: LRRC32 (Leucine Rich Repeat Containing 32 (LRRC32))

Reactivity: Mouse

Host: Rat

Clonality: Monoclonal

Conjugate: This LRRC32 antibody is un-conjugated

Application: Immunohistochemistry (IHC), Cytometry by Time of Flight (CyTOF), ELISA (Capture)

Clone: F011-5

Product Details anti-LRRC32 Antibody

Purification: The antibody was purified by affinity chromatography.

Isotype: IgG2a kappa

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: The antibody solution should be stored undiluted between 2°C and 8°C.

Target Details for LRRC32

Target: LRRC32 (Leucine Rich Repeat Containing 32 (LRRC32))

Alternative Name: GARP

Background: Glycoprotein A Repetitions Predominant (GARP), also known as leucine rich repeat containing protein 32 (LRC32), is a 80 kD type I membrane glycoprotein with 20 leucine rich repeats in the extracellular portion of the protein. GARP was found on the surface of megakaryocytes, platelets, and activated Tregs. It serves as a receptor for latent TGF-β. Recent evidence suggests that GARP may play a role in controlling suppressor function of Tregs. A mutation in GARP has been reported in a large Samaritan kindred with Usher syndrome type 1. In addition, it has been found that GARP mRNA is highly amplified in different tumors, which indicates that tumor cells may use GARP to express TGF-β or to capture TGF-β from their surroundings, resulting in local suppression of anti-tumor immune responses or the induction of Tregs.

Pathways: Activated T Cell Proliferation